What is HC Wainwright’s Estimate for DMRA FY2026 Earnings?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) – HC Wainwright dropped their FY2026 earnings estimates for Damora Therapeutics, Inc. Common Stock in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.73) per share for the year, down from their prior estimate of ($1.67). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock’s current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock’s Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.42) EPS and FY2027 earnings at ($1.70) EPS.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.12.

A number of other research firms also recently commented on DMRA. Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen raised Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research note on Sunday. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $46.38.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA opened at $24.07 on Monday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $15.00 and a 12 month high of $38.33. The firm has a market capitalization of $1.49 billion, a PE ratio of -7.14 and a beta of 1.52. The company’s 50 day simple moving average is $22.62 and its 200 day simple moving average is $25.68.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. Squarepoint Ops LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $303,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $7,398,000. Finally, Braidwell LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $42,146,000. Institutional investors own 14.20% of the company’s stock.

Insider Buying and Selling at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the transaction, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.40% of the stock is owned by company insiders.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.